prikaz prve stranice dokumenta Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease
  Download
PDF 341.7 KB
Scientific paper - Original scientific paper
Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 44 (2013); 94-99. https://doi.org/10.1016/j.pnpbp.2013.02.002
Mustapić, Maja; Presečki, Paola; Pivac, Nela; Mimica, Ninoslav; Hof, Patrick R.; Šimić, Goran; Folnegović-Šmalc, Vera; Muck-Šeler, Dorotea

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Mustapić, M., Presečki, P., Pivac, N., Mimica, N., Hof, P. R., Šimić, G. ... Muck Šeler, D. (2013). Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 44., 94-99. doi: 10.1016/j.pnpbp.2013.02.002

Mustapić, Maja, et al. "Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease." Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 44, 2013, pp. 94-99. https://doi.org/10.1016/j.pnpbp.2013.02.002

Mustapić, Maja, Paola Presečki, Nela Pivac, Ninoslav Mimica, Patrick R. Hof, Goran Šimić, Vera Folnegović Šmalc and Dorotea Muck Šeler. "Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease." Progress in Neuro-Psychopharmacology and Biological Psychiatry 44 (2013): 94-99. https://doi.org/10.1016/j.pnpbp.2013.02.002

Mustapić, M., et al. (2013) 'Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease', Progress in Neuro-Psychopharmacology and Biological Psychiatry, 44, pp. 94-99. doi: 10.1016/j.pnpbp.2013.02.002

Mustapić M, Presečki P, Pivac N, Mimica N, Hof PR, Šimić G, and sur.. Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry [Internet]. 2013 July 01 [cited 2024 November 29];44:94-99. doi: 10.1016/j.pnpbp.2013.02.002

M. Mustapić, et al., "Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease", Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 44, pp. 94-99, July 2013. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:515384. [Accessed: 29 November 2024]

Metadata
Title (english)Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease
AuthorMaja Mustapić
AuthorPaola Presečki
AuthorNela Pivac
AuthorNinoslav Mimica
AuthorPatrick R. Hof
AuthorGoran Šimić
AuthorVera Folnegović-Šmalc
AuthorDorotea Muck-Šeler
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
The noradrenergic system is involved in the etiology and progression of Alzheimer's disease (AD) but its role is still unclear. Dopamine beta-hydroxylase (DBH) as a catecholamine-synthesizing enzyme plays a central role in noradrenaline (NA) synthesis and turnover. Plasma DBH (pDBH) activity shows wide inheritable interindividual variability that is under genetic control. The aim of this study was to determine pDBH activity, DBH (C-970T; rs1611115) and DBH (C1603T; rs6271) gene polymorphisms in 207 patients with AD and in 90 healthy age-matched controls. Plasma DBH activity was lower, particularly in the early stage of AD, compared to values in middle and late stages of the disease, as well as to control values. Two-way ANOVA revealed significant effect of both diagnosis and DBH (C-970T) or DBH (C1603T) genotypes on pDBH activity, but without significant diagnosis×genotype interaction. No association was found between AD and DBH C-970T (OR=1.08, 95% CI 1.13-4.37; p=0.779) and C1603T (OR=0.89; 95% CI 0.36-2.20; p=0.814) genotypes controlled for age, gender, and ApoE4 allele. The decrease in pDBH activity, found in early phase of AD suggests that alterations in DBH activity represent a compensatory mechanism for the loss of noradrenergic neurons, and that treatment with selective NA reuptake inhibitors may be indicated in early stages of AD to compensate for loss of noradrenergic activity in the locus coeruleus.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleProgress in Neuro-Psychopharmacology and Biological Psychiatry
Numberingvol. 44, pp. 94-99
p-ISSN0278-5846
DOIhttps://doi.org/10.1016/j.pnpbp.2013.02.002
URN:NBNurn:nbn:hr:105:515384
Publication2013-07-01
Document URLhttps://doi.org/10.1016/j.pnpbp.2013.02.002
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-27 20:02:30